New International Field Of Research Established - Allergooncology

Research into the correlations between allergies and the development of
tumours - and possible benefits for future cancer treatments - has finally
become an established research discipline in its own right. That was the
conclusion at the 2nd International AllergoOncology Symposium, which took
place in Vienna at the weekend. The symposium's organiser, Prof.
Jensen-Jarolim, was extremely happy with the event, which was attended by
over 90 doctors and scientists from over 10 different countries. This
fascinating field of research, which she has succeeded in establishing with
support from the Austrian Science Fund FWF, has also been honoured with its
first review article in the international journal "Allergy".


Although scientists have been aware of the phenomenon for over 50 years, it
is only over the last three of these that there has been a dedicated field
of research looking into the influence of allergic reactions on the
development of tumours. Known as AllergoOncology, this discipline looks at
the ways that allergic reactions can inhibit the growth of cancer tumours.


This field of research was founded by Prof. Erika Jensen-Jarolim, head of
the Department of Pathophysiology at the Medical University of Vienna. Her
work on establishing AllergoOncology as a distinct field of medical research
began several years ago as part of a project run by the Austrian Science
Fund FWF.



Synergy & Symposium


Last weekend's International AllergoOncology Symposium in Vienna, the second
to be organised by Prof. Jensen-Jarolim, provided a host of international
immunologists and oncologists with the ideal opportunity to discuss
potential synergies in their work. The broad spread of topics covered at the
event included a presentation by Prof. Chris Parish from the John Curtin
School of Medical Research in Australia. He referred to a project during
which resistance to certain chemically induced tumours was achieved in a
mouse model through the administration of white blood cells, which are also
associated with allergies.


"Even if results from animal models cannot be transferred directly to
humans, projects like Prof. Parish's still demonstrate the enormous
therapeutic potential of AllergoOncology," comments Prof. Jensen-Jarolim.



Another project presented by Dr. Manuel Penichet, University of California,
which was carried out in cooperation with teams led by Prof. Hannah Gould,
King's College, London, and Prof. Jensen-Jarolim sought to combat breast
cancer. To do this, the team used a key characteristic of the special
antibodies that are jointly responsible for allergic reactions - IgE
antibodies. These antibodies have a highly reactive and long-lasting effect
against proteins that the body classes as unwanted. This IgE response can
also be accurately directed against protein structures in certain tumour
cells. This characteristic is being used by the team and can even be
enhanced by making specific adjustments to the antibody structure.


However, Prof. Jensen-Jarolim also felt that the potential of
AllergoOncology should be critically scrutinised during the symposium, and a
debate involving a panel of specialists led by the life science journalist
Johanna Award-Geissler provided the ideal solution. Prof. Jensen-Jarolim
explains: "To ensure a field of research survives in the long term, we need
to have people who are willing to be critical and we must put in place
consistent checks. That's why symposium participants were also presented
with data from a Viennese study of over 22,000 cancer patients, which had
been unable to identify any general link between mortality and the
concentration of IgE in serum, except in the case of lymphoma and leukaemia.
The reasons behind this will need to be analysed further."


A review article that was exclusively unveiled in advance at the weekend
showed just how much progress has already been made towards making
AllergoOncology an established field in international medicine and science.


The article is due to be published officially in the international journal
"Allergy" in a few weeks. From the FWF's perspective, both the symposium and
the state-of-the-art article demonstrate that providing early support for
newly emerging interdisciplinary fields of research such as AllergoOncology
really does make sense.


The full programme of the 2nd International AllergoOncology Symposium can be
found at: allergooncology.


Medizinische Universität WienInstitut für Pathophysiologie



Austrian Science Fund FWF


Buy Quinine Without Prescription